These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25775190)

  • 1. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.
    Young A; Khanna D
    Curr Opin Rheumatol; 2015 May; 27(3):241-8. PubMed ID: 25775190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status.
    Burt RK; Milanetti F
    Curr Opin Rheumatol; 2011 Nov; 23(6):519-29. PubMed ID: 21857226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment options in systemic Sclerosis (Scleroderma).
    Stummvoll GH
    Acta Med Austriaca; 2002; 29(1):14-9. PubMed ID: 11899748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of systemic sclerosis].
    van den Hoogen FH
    Z Rheumatol; 2006 Jul; 65(4):306, 308-10. PubMed ID: 16819640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the diagnosis and treatment of systemic sclerosis.
    Kowal-Bielecka O; Bielecki M; Kowal K
    Pol Arch Med Wewn; 2013; 123(1-2):51-8. PubMed ID: 23344666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.
    Dimitroulas T; Daoussis D; Garyfallos A; Sfikakis PP; Kitas GD
    Curr Med Chem; 2015; 22(16):1943-55. PubMed ID: 25850767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Fallet B; Walker UA
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term treatments for systemic sclerosis: what are the perspectives?].
    Mouthon L; Agard C; Garcia De La Peña-Lefebvre P; Guillevin L
    Ann Med Interne (Paris); 2002 Jun; 153(4):265-75. PubMed ID: 12218893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting vascular disease in systemic sclerosis.
    Kowal-Bielecka O
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on recent randomized clinical trials in systemic sclerosis.
    Boleto G; Avouac J; Allanore Y
    Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension.
    Opitz C; Klein-Weigel PF; Riemekasten G
    Vasa; 2011 Jan; 40(1):20-30. PubMed ID: 21283970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of methotrexate in patients with scleroderma and mixed connective tissue disease.
    Kowal-Bielecka O; Distler O
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S160-3. PubMed ID: 21044452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular Therapies in Systemic Sclerosis: Recent Progress.
    van Rhijn-Brouwer FC; Gremmels H; Fledderus JO; Radstake TR; Verhaar MC; van Laar JM
    Curr Rheumatol Rep; 2016 Feb; 18(2):12. PubMed ID: 26943351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous HSCT in systemic sclerosis: a step forward.
    Farge D; Gluckman E
    Lancet; 2011 Aug; 378(9790):460-2. PubMed ID: 21777973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.